TY - JOUR
T1 - Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery
AU - Bradaric, Christian
AU - Koppara, Tobias
AU - Müller, Arne
AU - Haller, Bernhard
AU - Ott, Ilka
AU - Cassese, Salvatore
AU - Fusaro, Massimiliano
AU - Kastrati, Adnan
AU - Laugwitz, Karl Ludwig
AU - Ibrahim, Tareq
N1 - Publisher Copyright:
© 2019 Pensoft Publishers. All rights reserved.
PY - 2019/12
Y1 - 2019/12
N2 - Aims: The aims of this study were to assess the incidence and predictors of superficial femoral artery (SFA) stent thrombosis (ST) in a large patient cohort. Methods and results: A total of 984 stented SFA lesions were retrospectively analysed in 717 patients. We observed an overall ST rate of 7.5% (74/984): 14% occurred early within 30 days after stenting, 51% during the first year thereafter and 35% later than one year. The estimated five-year probability of ST was 13.4% (95% confidence interval [CI]: 10.0% to 16.7%). Significant predictors of ST were stent length (hazard ratio [HR] 1.09, 95% CI: 1.06 to 1.11, p<0.001), lesion length (HR 1.10, 95% CI: 1.08 to 1.13, p<0.001), female gender (HR 1.79, 95% CI: 1.12 to 2.86, p=0.015), chronic total occlusion (CTO) (HR 4.21, 95% CI: 2.51 to 7.05, p<0.001), implantation of more than one stent (two stents: HR 6.06, 95% CI: 3.35 to 11.0, p<0.001; three or more stents: HR 16.83, 95% CI: 9.43 to 30.0, p<0.001) as well as lesion complexity criteria as expressed by TASC II C/D (HR 17.7, 95% CI: 5.56 to 56.1, p<0.001). Conclusions: ST after SFA stenting was a common adverse event in our cohort and peaked during the first year after stent implantation. Independent predictors of ST included lesion length and stent length, female gender, presence of CTO, number of implanted stents and lesion complexity.
AB - Aims: The aims of this study were to assess the incidence and predictors of superficial femoral artery (SFA) stent thrombosis (ST) in a large patient cohort. Methods and results: A total of 984 stented SFA lesions were retrospectively analysed in 717 patients. We observed an overall ST rate of 7.5% (74/984): 14% occurred early within 30 days after stenting, 51% during the first year thereafter and 35% later than one year. The estimated five-year probability of ST was 13.4% (95% confidence interval [CI]: 10.0% to 16.7%). Significant predictors of ST were stent length (hazard ratio [HR] 1.09, 95% CI: 1.06 to 1.11, p<0.001), lesion length (HR 1.10, 95% CI: 1.08 to 1.13, p<0.001), female gender (HR 1.79, 95% CI: 1.12 to 2.86, p=0.015), chronic total occlusion (CTO) (HR 4.21, 95% CI: 2.51 to 7.05, p<0.001), implantation of more than one stent (two stents: HR 6.06, 95% CI: 3.35 to 11.0, p<0.001; three or more stents: HR 16.83, 95% CI: 9.43 to 30.0, p<0.001) as well as lesion complexity criteria as expressed by TASC II C/D (HR 17.7, 95% CI: 5.56 to 56.1, p<0.001). Conclusions: ST after SFA stenting was a common adverse event in our cohort and peaked during the first year after stent implantation. Independent predictors of ST included lesion length and stent length, female gender, presence of CTO, number of implanted stents and lesion complexity.
KW - Critical limb ischaemia
KW - Femoropopliteal disease
KW - Stent thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85091376814&partnerID=8YFLogxK
U2 - 10.4244/EIJ-D-19-00187
DO - 10.4244/EIJ-D-19-00187
M3 - Article
AN - SCOPUS:85091376814
SN - 1774-024X
VL - 15
SP - E1107-E1114
JO - EuroIntervention
JF - EuroIntervention
IS - 12
ER -